Media Details

  • Home
  • Media
  • Details
  2020-08-25 19:27:50

Ho Wah Genting Berhad’s dietary supplement gets product registration approval

Company’s diversification plans being realised with Astramern Nutra V approval

KUALA LUMPUR, 25 AUGUST 2020 – Ho Wah Genting Berhad (“HWGB” or the “Company”) (KLSE:9601) is a step closer to making concrete the Company’s plans to diversify into the health-related industry following the product registration approval for Astramern Nutra V obtained from the National Pharmaceutical Regulatory Agency (“NPRA”).
The Company said the NPRA’s product registration approval for the dietary supplement, which comes in capsule form and comprises certain specified vitamins, is from 21 August 2020 to 21 August 2025
Chief Executive Officer of HWGB, Dato’ Lim Ooi Hong (Dato’ Aaron Lim) expressed: “The registration approval is key to getting the Astramern Nutra V dietary supplement into the market for distribution. We believe that as consumers seek out healthier lifestyle options, they would also want to have supplements that can boost their immunity”.
“This announcement also puts us one step closer to realising our diversification into the healthcare-related business that we announced earlier while also adding to another revenue stream for the Company”.
Astramern Nutra V contains “N-acetyl-L-cysteine”, which helps to replenish antioxidants that neutralises free radicals damaging to cells and tissues while other properties include combatting numerous other ailments caused by oxidative stress, such as heart disease, infertility and some psychiatric condition.
The key ingredients in Astramern Nutra V include Vitamins C and D as well as Quercetin, which may improve inflammation, blood pressure, exercise performance, and blood sugar control together with brain-protective, anti-allergy and anticancer properties.
HWGB had in early 2020 appointed San Diego-based and Nasdaq-listed Guardion Health Sciences, Inc (“GHSI”) to design and manufacture two dietary supplements, Astramern Nutra V and Astramern Nutra H, in which the Company has exclusive use and ownership. The Company has also signed a Manufacturing and Supply Agreement with GHSI for both supplements.
The Company said an update on the product registration approval of Astramern Nutra H, also in capsule form and containing certain specified Chinese herbs, will be made in due course.

Ho Wah Genting Berhad (“HWGB” or the “Company”) is principally engaged in investment holdings and the provision of management services to its subsidiaries. The Company had on 30 June 2020 diversified its existing businesses to include healthcare related industry which mainly involved in Health Supplement, Biotechnology and Health Technology. In addition, the Company and its subsidiaries (“HWGB Group” or the “Group”) are also engaging in the businesses of Investment holdings; manufacturing of wires and cables and moulded power supply cord sets and cable assemblies for electrical and electronic devices and equipment; Trading of wires and cables; and travel agent and tour related services.
Guardian Health Sciences, Inc. (NASDAQ: GHSI), is a specialty health sciences company that develops medical foods and medical devices in the ocular health space and develops nutraceutical products that the Company believes provide supportive health benefits to consumers. Located in San Diego, the company combines targeted nutrition with innovative, evidence-based diagnostic technology. Guardion boasts one of the most impressive Scientific and Medical Advisory Boards in the world and is led by seasoned business executives with many years of experience. This combination of expertise and scientific knowledge has catapulted Guardion into a leadership position within the eye care industry and the nutrition marketplace.

Issued by: Esente Communications (M) Sdn. Bhd. on behalf of Ho Wah Genting Berhad
Date: 25 August 2020

For more information, please contact:
Tan Hoay Ming
Associate Director, Public Relations
Tel : +603 64199501 /+603 64199502